Skip to main content

Table 1 EQ-5D-5L individual dimensions – percentage of patients reporting problems in ESK + AD and AD + PBO groups

From: Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant

Dimension

ESK + AD (%)

AD + PBO (%)

% difference (95% CI)

 

Baseline (n = 114)

Day 15 (n = 111)

Day 28 (n = 104)

Baseline (n = 109)

Day 15 (n = 104)

Day 28 (n = 100)

Day 15

Day 28

Mobility

28.1

18.9

10.6

34.9

24.0

25.0

-5.1 (-16.1, 5.9)

-14.4 (-24.8, -4.1)

Self-care

53.5

27.0

13.5

53.2

50.0

32.0

-23.0 (-35.6, -10.3)

-18.5 (-29.8, -7.3)

Usual activities

94.8

71.2

51.9

92.7

79.8

72.0

-8.6 (-20.1, 2.8)

-20.1 (-33.1, -7.1)

Pain/Discomfort

68.5

52.3

35.6

74.3

59.6

54.0

-7.4 (-20.6, 5.9)

-18.4 (-31.8, -5.0)

Anxiety/Depression

98.3

84.7

69.2

99.9

86.5

78.0

-1.9 (-11.2, 7.5)

-8.8 (-20.8, 3.3)

  1. AD antidepressant, CI confidence interval, EQ-5D-5L European Quality of Life-5 Dimension-5 Level, ESK esketamine, PBO placebo